The management of clinical stage III and IVa esophageal
cancer has evolved in the past 2 decades. Based on the Cross
trial, neoadjuvant chemoradiation, followed by surgical
resection has become standard. For medically inoperable,
definitive chemoradiation is most commonly used. The
standard radiation dose is 50.4 Gy although trials of doseescalation
are ongoing. At the current time, there are no
definitive biomarkers to predict response.
Keywords: Esophageal cancer, Radiation therapy,
Chemotherapy, Dose-escalation
Primary Language | English |
---|---|
Journal Section | Articles |
Authors | |
Publication Date | September 30, 2015 |
Published in Issue | Year 2015 Special Issue :1 Oncology |